Cision PR Newswire
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
News provided byLeap Therapeutics, Inc.
Nov 21, 2023, 7:00 AM ET
CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.
Leap Presentation Details:
Piper Sandler 35th Annual Healthcare Conference
Date: Tuesday, November 28, 2023
Time: 8:00 a.m. Eastern Time
A live webcast of the fireside chat may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-35th-annual-healthcare-conference-301991880.html
SOURCE Leap Therapeutics, Inc.
NOTE: This content is not written by or endorsed by "KARD/KTVE", its advertisers, or Nexstar Media Inc.